{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:04:30Z","timestamp":1779339870858,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41431-018-0300-6","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T05:12:03Z","timestamp":1541999523000},"page":"442-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7754-6413","authenticated-orcid":false,"given":"T\u00f5nis","family":"Tasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart","family":"Kals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reedik","family":"M\u00e4gi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker M.","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toomas","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarmo","family":"Puurand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maido","family":"Remm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00f5nu","family":"Esko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Metspalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaak","family":"Vilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-3102","authenticated-orcid":false,"given":"Lili","family":"Milani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"300_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","volume":"38","author":"JC Bouvy","year":"2015","unstructured":"Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437\u201353.","journal-title":"Drug Saf"},{"key":"300_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2147\/CEOR.S115689","volume":"8","author":"F Batel Marques","year":"2016","unstructured":"Batel Marques F, Penedones A, Mendes D, Alves C. A systematic review of observational studies evaluating costs of adverse drug reactions. Clin Outcomes Res CEOR. 2016;8:413\u201326.","journal-title":"Clin Outcomes Res CEOR"},{"key":"300_CR3","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1001\/jama.2017.5150","volume":"317","author":"NS Downing","year":"2017","unstructured":"Downing NS, Shah ND, Aminawung JA, et al. Postmarket safety events among novel therapeutics approved by the US food and drug administration between 2001 and 2010. JAMA. 2017;317:1854\u201363.","journal-title":"JAMA"},{"key":"300_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","volume":"20","author":"VM Lauschke","year":"2017","unstructured":"Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. AAPS J. 2017;20:4.","journal-title":"AAPS J"},{"key":"300_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2217\/PGS.15.54","volume":"16","author":"SL Chan","year":"2015","unstructured":"Chan SL, Jin S, Loh M, Brunham LR. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. Pharmacogenomics. 2015;16:1161\u201378.","journal-title":"Pharmacogenomics"},{"key":"300_CR6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2217\/pgs.14.117","volume":"15","author":"ED Esplin","year":"2014","unstructured":"Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics. 2014;15:1771\u201390.","journal-title":"Pharmacogenomics"},{"key":"300_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature15817","volume":"526","author":"MV Relling","year":"2015","unstructured":"Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343\u201350.","journal-title":"Nature"},{"key":"300_CR8","first-page":"217","volume":"14","author":"E Ramos","year":"2014","unstructured":"Ramos E, Doumatey A, Elkahloun AG, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharm J. 2014;14:217\u201322.","journal-title":"Pharm J"},{"key":"300_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/ejhg.2017.51","volume":"25","author":"M Mitt","year":"2017","unstructured":"Mitt M, Kals M, P\u00e4rn K, et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. Eur J Hum Genet. 2017;25:869\u201376.","journal-title":"Eur J Hum Genet"},{"key":"300_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/jpm5020096","volume":"5","author":"L Leitsalu","year":"2015","unstructured":"Leitsalu L, Alavere H, Tammesoo M-L, Leego E, Metspalu A. Linking a population biobank with national health registries-the estonian experience. J Pers Med. 2015;5:96\u2013106.","journal-title":"J Pers Med"},{"key":"300_CR11","doi-asserted-by":"publisher","first-page":"E327","DOI":"10.1073\/pnas.1619052114","volume":"114","author":"MH Guo","year":"2017","unstructured":"Guo MH, Nandakumar SK, Ulirsch JC, et al. Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. Proc Natl Acad Sci USA. 2017;114:E327\u2013E336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"300_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/humu.21454","volume":"32","author":"SC Sim","year":"2011","unstructured":"Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat. 2011;32:526\u201331.","journal-title":"Hum Mutat"},{"key":"300_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","volume":"92","author":"M Whirl-Carrillo","year":"2012","unstructured":"Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"300_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"300_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1215040","volume":"335","author":"DG MacArthur","year":"2012","unstructured":"MacArthur DG, Balasubramanian S, Frankish A, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012;335:823\u20138.","journal-title":"Science"},{"key":"300_CR16","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/nar\/gkg585","volume":"31","author":"AE Kel","year":"2003","unstructured":"Kel AE, G\u00f6ssling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res. 2003;31:3576\u20139.","journal-title":"Nucleic Acids Res"},{"key":"300_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/bib\/bbn016","volume":"9","author":"E Wingender","year":"2008","unstructured":"Wingender E. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinformatics. 2008;9:326\u201332.","journal-title":"Brief Bioinformatics"},{"key":"300_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium.","year":"2012","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57\u201374.","journal-title":"Nature"},{"key":"300_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/npjgenmed.2015.7","volume":"1","author":"GP Twist","year":"2016","unstructured":"Twist GP, Gaedigk A, Miller NA, et al. Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. NPJ Genom Med. 2016;1:15007.","journal-title":"NPJ Genom Med"},{"key":"300_CR20","doi-asserted-by":"publisher","first-page":"e64683","DOI":"10.1371\/journal.pone.0064683","volume":"8","author":"X Jia","year":"2013","unstructured":"Jia X, Han B, Onengut-Gumuscu S, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE. 2013;8:e64683.","journal-title":"PLoS ONE"},{"key":"300_CR21","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. https:\/\/www.R-project.org\/ ."},{"key":"300_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","journal-title":"Gigascience"},{"key":"300_CR23","unstructured":"World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC\/DDD). Geneva: WHO; 2006."},{"key":"300_CR24","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336\u20137.","journal-title":"Bioinformatics"},{"key":"300_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrg2344","volume":"9","author":"MI McCarthy","year":"2008","unstructured":"McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356\u201369.","journal-title":"Nat Rev Genet"},{"key":"300_CR26","unstructured":"Dewey M. metap: meta-analysis of significance values. Vienna, Austria: R Foundation for Statistical Computing; 2017."},{"key":"300_CR27","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1101\/gr.137323.112","volume":"22","author":"AP Boyle","year":"2012","unstructured":"Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790\u20137.","journal-title":"Genome Res"},{"key":"300_CR28","doi-asserted-by":"publisher","first-page":"D793","DOI":"10.1093\/nar\/gks1055","volume":"41","author":"A Kamburov","year":"2013","unstructured":"Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res. 2013;41:D793\u2013800.","journal-title":"Nucleic Acids Res"},{"key":"300_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/gim.2016.33","volume":"19","author":"M Kozyra","year":"2017","unstructured":"Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med 2017;19:20\u201329.","journal-title":"Genet Med"},{"key":"300_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tips.2015.10.006","volume":"37","author":"VM Lauschke","year":"2016","unstructured":"Lauschke VM, Ingelman-Sundberg M. Precision medicine and rare genetic variants. Trends Pharmacol Sci. 2016;37:85\u201386.","journal-title":"Trends Pharmacol Sci"},{"key":"300_CR31","first-page":"6","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharm J. 2005;5:6\u201313.","journal-title":"Pharm J"},{"key":"300_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/FPC.0000000000000118","volume":"25","author":"JM Barbarino","year":"2015","unstructured":"Barbarino JM, Kroetz DL, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genom. 2015;25:205\u201321.","journal-title":"Pharmacogenet Genom"},{"key":"300_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2331-y","volume":"17","author":"CB Small","year":"2017","unstructured":"Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis. 2017;17:256.","journal-title":"BMC Infect Dis"},{"key":"300_CR34","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","volume":"43","author":"FF Gonz\u00e1lez-Galarza","year":"2015","unstructured":"Gonz\u00e1lez-Galarza FF, Takeshita LYC, Santos EJM, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43:D784\u2013D788.","journal-title":"Nucleic Acids Res"},{"key":"300_CR35","first-page":"296","volume":"47","author":"RE Handsaker","year":"2015","unstructured":"Handsaker RE, Doren VVan, Berman JR, et al. Large multiallelic copy number variations in humans. Nat Publ Group. 2015;47:296\u2013303.","journal-title":"Nat Publ Group"},{"key":"300_CR36","doi-asserted-by":"crossref","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000; 356: 1255\u20139.","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"300_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373\u20139.","journal-title":"J Clin Epidemiol"},{"key":"300_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/FPC.0000000000000172","volume":"25","author":"K Fujikura","year":"2015","unstructured":"Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. Pharm Genom. 2015;25:584\u201394.","journal-title":"Pharm Genom"},{"key":"300_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/genes5020430","volume":"5","author":"DF Carr","year":"2014","unstructured":"Carr DF, Alfirevic A, Pirmohamed M. Pharmacogenomics: current state-of-the-art. Genes. 2014;5:430\u201343.","journal-title":"Genes"},{"key":"300_CR40","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/clpt.2014.137","volume":"96","author":"LJ Rasmussen-Torvik","year":"2014","unstructured":"Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multi-center pilot for pre-emptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014;96:482\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"300_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.350","volume":"100","author":"WS Bush","year":"2016","unstructured":"Bush WS, Crosslin DR, Owusu-Obeng A, et al. Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clin Pharmacol Ther. 2016;100:160\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"300_CR42","doi-asserted-by":"publisher","first-page":"e0182138","DOI":"10.1371\/journal.pone.0182138","volume":"12","author":"K Lakiotaki","year":"2017","unstructured":"Lakiotaki K, Kanterakis A, Kartsaki E, Katsila T, Patrinos GP, Potamias G. Exploring public genomics data for population pharmacogenomics. PLoS ONE. 2017;12:e0182138.","journal-title":"PLoS ONE"},{"key":"300_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-018-0157-3","volume":"12","author":"M Ingelman-Sundberg","year":"2018","unstructured":"Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genom. 2018;12:26.","journal-title":"Hum Genom"},{"key":"300_CR44","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2217\/pgs.14.102","volume":"15","author":"C Mizzi","year":"2014","unstructured":"Mizzi C, Peters B, Mitropoulou C, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014;15:1223\u201334.","journal-title":"Pharmacogenomics"},{"key":"300_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/clpt.2008.61","volume":"84","author":"I Song","year":"2008","unstructured":"Song I, Shin H, Shim E, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"300_CR46","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","volume":"22","author":"L Gong","year":"2012","unstructured":"Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharm Genom. 2012;22:820\u20137.","journal-title":"Pharm Genom"},{"key":"300_CR47","first-page":"25","volume":"11","author":"S Laechelt","year":"2011","unstructured":"Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharm J. 2011;11:25.","journal-title":"Pharm J"},{"key":"300_CR48","first-page":"396","volume":"13","author":"TD Nguyen","year":"2013","unstructured":"Nguyen TD, Markova S, Liu W, et al. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharm J. 2013;13:396\u2013402.","journal-title":"Pharm J"},{"key":"300_CR49","first-page":"251","volume":"13","author":"ML Becker","year":"2013","unstructured":"Becker ML, Elens LLFS, Visser LE, et al. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharm J. 2013;13:251.","journal-title":"Pharm J"},{"key":"300_CR50","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0026-895X(24)12045-7","volume":"28","author":"E St\u00f6rmer","year":"2000","unstructured":"St\u00f6rmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos Biol Fate Chem. 2000;28:1168\u201375.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"300_CR51","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bcp.12348","volume":"78","author":"Y Ji","year":"2014","unstructured":"Ji Y, Schaid DJ, Desta Z, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014;78:373\u201383.","journal-title":"Br J Clin Pharmacol"},{"key":"300_CR52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.jcp.0000145341.30547.f0","volume":"24","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Henckel H-B, Meineke I, Roots I, Brockm\u00f6ller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004;24:647\u201352.","journal-title":"J Clin Psychopharmacol"},{"key":"300_CR53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.psychres.2011.12.034","volume":"198","author":"S Narasimhan","year":"2012","unstructured":"Narasimhan S, Aquino TD, Multani PK, Rickels K, Lohoff FW. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2012;198:112\u20135.","journal-title":"Psychiatry Res"},{"key":"300_CR54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/bcpt.12827","volume":"121","author":"A Taranu","year":"2017","unstructured":"Taranu A, Asmar KE, Colle R, et al. The catechol-O-methyltransferase val(108\/158)met genetic polymorphism cannot be recommended as a biomarker for the prediction of venlafaxine efficacy in patients treated in psychiatric settings. Basic Clin Pharmacol Toxicol. 2017;121:435\u201341.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"300_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.47","volume":"5","author":"JM Biernacka","year":"2015","unstructured":"Biernacka JM, Sangkuhl K, Jenkins G, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2015;5:e553.","journal-title":"Transl Psychiatry"},{"key":"300_CR56","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/npp.2011.257","volume":"37","author":"A Menke","year":"2012","unstructured":"Menke A, Domschke K, Czamara D, et al. Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology. 2012;37:797\u2013807.","journal-title":"Neuropsychopharmacology"},{"key":"300_CR57","doi-asserted-by":"crossref","unstructured":"Hamada S, Futamura N, Ikuta K, Urakawa H, Kozawa E, Ishiguro N, et al. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLos ONE. 2014; 9: e96391.","DOI":"10.1371\/journal.pone.0096391"},{"key":"300_CR58","first-page":"52","volume":"4","author":"A Asthma","year":"2012","unstructured":"Asthma A, Res I, Kindi MA, Limaye V, Hissaria P. Meloxicam-induced rhabdomyolysis in the context of an acute ross river viral. Infection. 2012;4:52\u201354.","journal-title":"Infection"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41431-018-0300-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-018-0300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-018-0300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:17:56Z","timestamp":1775265476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-018-0300-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1038\/s41431-018-0300-6","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Broad informed consent from Biobank participants has given the Estonian Genome Center permission for continuous updates of epidemiologic data through periodical linking to central electronic health record (EHR) databases and local hospital information systems [\n                      \n                      ]. The study was conducted in accordance with good ethical standards, and was approved by the Ethics Committee of the University of Tartu (protocol nr 234\/T-12).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}